News Spark files revolutionary gene therapy with FDA Luxturna granted six-month priority review by FDA.
News Disappointment as government delays pharma-friendly policies Proposals fall short of ambitions of Accelerated Access Review.
News Amicus to file Fabry drug after FDA changes mind Regulator drops demand for further phase 3 trial.
News The curious case of Mylotarg: Pfizer's leukaemia drug set to... Mylotarg backed by advisers after withdrawal in 2010.
Events Partner Content Clinical Trial Supply East Coast 2017 The 15th Annual CTS East Coast event builds on last year’s conference, Arena’s biggest East Coast CTS event to date.
News Relief for AZ as Truqap hits the spot in prostate cancer After a disappointing result with Truqap in triple-negative breast cancer, AstraZeneca chalks up a win in prostate cancer
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends
